ArticleBioactive materials2025
Cu-DHM nanozymes treat flap ischemia-reperfusion injury by amplifying immune modulation in a cascade manner and inhibiting cell apoptosis.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exosomes orchestrate immune homeostasis in acute ischemia-reperfusion flap injury and chronic wounds: the TLR4/NF-κB-STAT3 R-ratio balance decision model, engineering optimization and translational clinical strategy.Frontiers in immunology · 2026Pooled it
- Beyond Biomimetics: Pathology-Informed Engineering Rescues Reconstituted HDL From Inflammatory Dysfunction for Sepsis Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advanced metal-phenolic networks for tissue regeneration: opportunities and challenges.Journal of nanobiotechnology · 2026Review
- Mitophagy activation for jawbone radiation injury therapy via angiogenesis/osteogenesis-active nanozymes.Science China. Life sciences · 2026Article
- Regenerative Approach for Improving Flap Survival: Perspective of Angiogenesis.Biomimetics (Basel, Switzerland) · 2026Review
- Targeting engineered cell membrane camouflaged gallic acid-cerium nanozyme for intercepting the inflammation-free radical vicious cycle in atherosclerosis.Journal of nanobiotechnology · 2026Article
- Renal-tubular-mitochondrial sequentially targeted nanoagent breaks the vicious cycle of oxidative stress and mtDNA-driven inflammation in acute kidney injury therapy.Journal of nanobiotechnology · 2026Article
- Mechanisms of mitochondrial dysfunction and protective strategies in skin flap ischemia-reperfusion injury.Frontiers in pharmacology · 2026Review
- All Nanozyme-Based Cascade Reactions for Biomedical Applications: from Self-Cascading Nanozyme to Immobilized Cascade Nanozyme.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flap ischemia-reperfusion (I/R) injury triggers intense inflammatory responses and oxidative stress following blood flow restoration, often resulting in tissue dysfunction. Currently, no effective and widely recognized treatment strategies are available in clinical practice. During flap I/R injury, macrophages, T cells, and neutrophils form a complex regulatory network that jointly participates in inflammatory responses, immune modulation, and tissue repair. Achieving a dynamic balance among these three cell types is critical for flap survival and healing. In this study, a novel Cu-DHM NP metal-polyphenol nanozyme that effectively amplifies immune modulation in a cascade manner, inhibits apoptosis, and treats flap I/R injury was developed. Leveraging their excellent antioxidant properties and SOD-like and CAT-like enzyme activities, Cu-DHM NPs eliminate ROS, alleviate intracellular oxidative stress, protect mitochondrial function, and reduce apoptosis. Moreover, Cu-DHM NPs can regulate the immune microenvironment, cascade and amplify the immunomodulatory effect between macrophages and Naive CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.